Terri Nutt, MD
Dermatology · San Antonio, TXNPI 1073564456
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Johnson & Johnson at 32.0% of the total.
Across 293 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Lilly USA, LLC$672
- AbbVie$609
- UCB, Inc.$321
- Sun Pharmaceutical Industries Inc.$301
- Dermavant Sciences, Inc.$298
- plus $2K from 20 others
Across 29 payments — averaging $2691.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endo Pharmaceuticals Inc.$71K
- LEO Pharma AS$4K
- Boehringer Ingelheim International GmbH$3K
What the payments were for
- Food & beverage$6,22695%
- Education$3105%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 118 | $2,092 |
| Lilly USA, LLC | 26 | $672 |
| AbbVie | 29 | $609 |
| UCB, Inc. | 10 | $321 |
| Sun Pharmaceutical Industries Inc. | 13 | $301 |
| Dermavant Sciences, Inc. | 12 | $298 |
| LEO Pharma Inc. | 9 | $243 |
| Sanofi | 7 | $231 |
| Hill Dermaceuticals, Inc. | 2 | $230 |
| E.r. Squibb & Sons, L.L.C. | 5 | $218 |
| Amgen | 10 | $209 |
| Novartis | 13 | $198 |
| Pfizer | 5 | $137 |
| Galderma Laboratories, L.p. | 9 | $133 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 6 | $114 |
| Incyte Corporation | 4 | $108 |
| Kerecis Limited | 1 | $51 |
| Kyowa Kirin, Inc. | 2 | $44 |
| Organon | 2 | $44 |
| Journey Medical Corporation | 2 | $40 |
| Boehringer Ingelheim | 2 | $37 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $32 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| LNHC, Inc | 1 | $18 |
| Encore Dermatology Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,536 in reported general payments places this provider in the 60th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 22 | $204,653 |
| OtezlaApremilast | 17 | $84,504 |
| Dupixent PenDupilumab | 13 | $49,220 |
| Clobetasol Propionate | 87 | $3,177 |
| Doxycycline Hyclate | 88 | $2,858 |
| Dutasteride | 65 | $1,701 |
| Metronidazole | 36 | $1,527 |
| Tretinoin | 13 | $1,261 |
| Fluorouracil | 21 | $1,143 |
| Tacrolimus | 12 | $1,083 |
| Ketoconazole | 44 | $1,025 |
| Minoxidil | 77 | $775 |
| Triamcinolone Acetonide | 85 | $629 |
| CiclopiroxCiclopirox Olamine | 12 | $594 |
| Betamethasone Dipropionate | 11 | $592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $209 | $84,50417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,098 dermatology providers in Texas.
Other dermatology in San Antonio
- William CragunSan Antonio$2.2M
- Emily BeckerSan Antonio$1.2M
- Lindsey FinkleaSan Antonio$435K
- John BrowningSan Antonio$351K
- Vivian BucaySan Antonio$241K
- Annabelle GarciaSan Antonio$215K
- Edward LainAustin$2.5M
- Alpesh DesaiHouston$1.6M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.